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Itisnowwellestablishedthatthedevelopmentandprogressionofavarietyofhumanmalignanciesareassociatedwithdysregulated
activity of the insulin-like growth factor (IGF) system. In this regard, promising drugs have been developed to target the IGF-I
receptor or its ligands. These therapies are limited by the development of insulin resistance and compensatory hyperinsulinemia,
which in turn, may stimulate cancer growth. Novel therapeutic approaches are, therefore, required. Synthetic PPAR-γ agonists,
such as thiazolidinediones (TZDs), are drugs universally used as antidiabetic agents in patients with type 2 diabetes. In addition
of acting as insulin sensitizers, PPAR-γ agonists mediate in vitro and in vivo pleiotropic anticancer eﬀe c t s .A tl e a s ts o m eo ft h e s e
eﬀects appear to be linked with the downregulation of the IGF system, which is induced by the cross-talk of PPAR-γ agonists with
multiple components of the IGF system signaling. As hyperinsulinemia is an emerging cancer risk factor, the insulin lowering
action of PPAR-γ agonists may be expected to be also beneﬁcial to reduce cancer development and/or progression. In light of these
evidences, TZDs or other PPAR-γ agonists may be exploited in those tumors “addicted” to the IGF signaling and/or in tumors
occurring in hyperinsulinemic patients.
Copyright © 2009 A. Belﬁore et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Traditional anticancer therapies as chemotherapy and radia-
tions are often unable to eradicate advanced cancers. Novel
therapeutic modalities are, therefore, needed in the aim
to lower the threshold for cancer cell death induced by
traditional therapies.
The insulin-like growth factor (IGF) system has recently
emerged as having a relevant role in cancer development and
progression and in the resistance to drug-induced apoptosis.
It is now well established that the IGF system is dysreg-
ulated/overactivated in a variety of human malignancies.
Common mechanisms of dysregulation include autocrine
and/or paracrine secretion of insulin-like growth factors
(IGF-I and IGF-II) and overexpression of their cognate
receptors (the IGF-I receptor, IGF-IR, and the closely related
insulin receptor, IR). One viable anticancer strategy is,
therefore, to target the various IGF system components that
are dysregulated and that sustain increased constitutive IGFs’
signaling in cancer cells.
Most anticancer strategies designed to curtail the IGF
systemdysregulationhavebeendesignedtotargettheIGF-IR
[1–3]. In this regard, promising drugs have been developed,
as small molecules with speciﬁc IGF-IR tyrosine kinase
inhibiting activity and antiIGF-IR monoclonal antibodies
that cause ligand binding inhibition and receptor downregu-
lation and degradation. Other approaches have chosen IGF-
I and/or IGF-II as targets. Some of these compounds have
shown promising activity in preclinical studies and are now
being evaluated in phase I and phase II clinical trials. The
aberrant expression of the insulin receptor isoform A (IR-
A) in malignant cells has also been advocated as a target.
One limit of all these targeted therapies is the occurrence
of insulin resistance and compensatory hyperinsulinemia
caused by either direct impairment of the IR function or by
growth hormone (GH) increase in response to the reduced
IGFs signaling [4, 5].
Unfortunately, several epidemiological studies have
shown that a high level of circulating insulin (hyperinsu-
linemia) is associated with an increased risk for a number2 PPAR Research
of malignancies [6]. Moreover, hyperinsulinemia is very
common in western societies because closely associated with
obesity and type 2 diabetes [4, 7, 8].
Thiazolidinediones (TZDs) are synthetic PPARs agonists
that are widely used as antidiabetic agents in patients with
type 2 diabetes. These drugs ameliorate tissue sensitivity
to insulin and, indirectly, cause a reduction of circulating
insulin levels. Moreover, TZDs, as other PPAR-γ agonists,
such as the prostanoid 15d-PGJ2 [9], induce a variety of
favorable changes (growth arrest, apoptosis, and/or partial
rediﬀerentiation) in several malignancies, including liposar-
coma,andcancersofthebreast,colon,pancreas,andprostate
[10–18].
We will herein review the available evidences indicating
that these anticancer eﬀects of PPAR-γ agonists are partially
related to the downregulation of the IGF system activity at
variouslevels.Onthebasisoftheseevidences,wesuggestthat
TZDs or other PPAR-γ agonists may be a useful adjunct to
the therapy of IGFs-driven malignancies.
2. The IGF System andIts Role in Cancer
2.1. Components of the IGF System. The IGF system is
composed by at least two closed related receptors, three
ligands (insulin and insulin-like growth factors I and II)
and six ligand-binding proteins (IGF-BPs) (Figure 1(a))[ 19,
20]. The two receptors, the type I IGF receptor (IGF-IR)
and the insulin receptor (IR) are tetrameric glycoproteins
composed of two extracellular α- and two transmembrane
β-subunits linked by disulﬁde bonds [21, 22]. The α-
subunits contain the ligand binding site while the β-subunits
contain a tyrosine kinase domain. These two receptors share
more than 50% overall amino acid sequence homology
and 84% homology in the tyrosine kinase domains. The
transmembrane domain has a crucial role in recruiting
intracellular mediators [23] through two conserved tyrosine
residues.
The IR exists in two isoforms that diﬀer for the inclusion
(isoform B or IR-B) or the exclusion (isoform A or IR-A) of
12 aminoacid residues encoded by exon 11 [24, 25]. These
t w oI Ri s o f o r m sa p p e a rt oh a v ed i ﬀerent ligand speciﬁcity
and tissue distribution [26–29].
Because of the high sequence similarity between the IR
and the IGF-IR [21, 22], an IR hemireceptor may assemble
notonlywithasecondIRhemireceptorbutalsowithanIGF-
IR hemireceptor, forming a hybrid IR/IGF-IR receptor (HR).
The signaling of these receptors regulates crucial func-
tions of multicellular organisms, such as glucose metabolism
and growth and life span in response to nutrients [30, 31].
IGF-I and IGF-II expressions were ﬁrst analyzed in
rodents where IGF-II gene is widespread expressed in
prenatal period and diminishes dramatically after birth. In
contrast, IGF-I levels are low during the prenatal period and
increase signiﬁcantly during puberty and adulthood. The
overall picture of IGFs expression in rodents initially led to
the associate IGF-II as a fetal growth factor and IGF-I as an
adult growth factor. However, this expression pattern is not
observed in humans, as both IGF-I and IGF-II are produced
in human tissue during lifetime period.
T h eh u m a nI G F - Ig e n ei sl o c a t e do nc h r o m o s o m e1 2
and has two promoter sites [20] .M a t u r eI G F - Ii sa7 . 7k D a
protein that has 62% homology with IGF-II in its amino acid
sequence [20]. The human IGF-II is encoded by a 9-exons
gene located on chromosome 11p15. Multiple transcripts
are synthesized as a result of alternate promoter usage [32].
Promoter 1 is active only in adult liver, while P2-4 promoters
are active in most fetal tissues. Activation of P3 and P4
p r o m o t e r si sc o m m o ni nc a n c e rc e l l s[ 33].
The biological activity of the IGF ligands is also mod-
ulated by a family of high-aﬃnity IGF binding proteins
(IGFBP 1–6). IGFBP-3 is the predominant binding protein
expressed in serum, and most circulating IGF-I and IGF-II
are bound in a ternary complex with IGFBP-3 and a third
component, the acid-labile subunit (ALS). The IGFBPs rule
IGF action by increasing the half-lives of circulating IGFs, by
controlling their availability for receptor binding. IGFBPs-1–
4 have similar aﬃnities for IGF-I and IGF-II whereas IGFBP-
5 and 6 bind IGF-II with a 10- and 100-fold higher aﬃnity,
respectively, than IGF-I [34–36].
A detailed description of the diﬀerent components of the
IGF system and of the complex signaling network activated
by ligand binding to the IGF-IR and the IR is beyond the
scope of this article and can be found elsewhere [37]. We
will herein provide a brief overview of the major signaling
pathways common to both receptors in order to describe
the consequences of the IGF system dysregulation frequently
observed in cancer and the way PPAR-γ agonists may aﬀect
these pathways.
2.2. The IGF System Signaling Pathways. Both IGF-I and
insulin bind to the extracellular α-subunit of their cognate
receptor and induce a conformational change that causes
the activation of the receptor tyrosine-kinase and the
autophosphorylation of tyrosine residues of the intracellular
β-subunit at the level of the catalytic domain, the juxtamem-
brane domain and the C-terminus [38]. Tyrosine phos-
phorylation causes the recruitment of several intracellular
substrates which function as either docking proteins (IRS-
1, IRS-2) or adaptors (SHC, Grb2) for other intracellular
proteins that have speciﬁc recognition domains, termed Src-
homology-2 (SH2) domains [39]. In turn these substrates
bind and recruit other intracellular proteins (Figure 1(b))
[40].
IRS-1, which binds to phosphotyrosine residues in the
juxtamembrane domain with its Phosphotyrosine Binding
(PTB) domain, has 20–22 potential tyrosine phosphoryla-
tion sites surrounded by possible binding sites for SH2-
proteins [39]. Among the relevant SH2 domain-containing
proteins, the phosphatidylinositol-3 kinase (PI3K) [41]a n d
the GTPase activating protein (GAP) of Ras [42] originate
the two major signaling pathways, common to both the IR
and the IGF-IR.
The PI3K binds to IRS proteins through its regula-
tory subunit (p85), which then recruits the PI3K catalytic
subunit (p110) to the plasma membrane, where it phos-
phorylates phosphatidylinositol-(4,5)-bisphospate (PIP2) to
phosphatidylinositol-(3,4,5)-trisphosphate (PIP3). PIP3, in




























Figure 1: The IGF system: receptors, ligands, and signaling pathways. (a) Schematic representation of the major receptors and ligands involved in
the IGF system. Insulin receptor isoforms (IR-A or IR-B) binds insulin with high aﬃnity, while IGF-I receptor (IGF-IR) binds IGF-I and IGF-
II (left). In cells expressing both IR and IGF-IR, IR hemireceptors may heterodimerize with IGF-IR hemireceptors, leading to the formation
of hybrid IR/IGF-IRs (HRs), which bind IGF-I and IGF-II with high aﬃnity and insulin with a much lower aﬃnity (right). (b) The IGF
system signaling pathways. Schematic representation of the two major signaling pathways involved in IGF system. IGF-I, IGF-II, and insulin
bind to their cognate receptors, leading to the activation of the PI3K/Akt/mTOR pathway and of the Ras/Raf-1/MEK/ERK pathway.
by the phosphoinositide-dependent kinase 1 (PDK1). Akt
activation is crucial for the regulation of glucose metabolism
but also for the regulation of cell size, proliferation and
survival by regulating metabolic enzymes, such as glycogen
synthase kinase 3 and 6-phosphofructo-2-kinase and apop-
tosis modulators, such as BAD. Akt also regulates mRNA
translation through the raptor-mTOR pathway, which also
has a central role in cell growth and metabolism [43, 44].
Activationoftheraptor-mTORcomplexrequiresthebinding
with Rheb (Ras homolog enriched in brain), a GTP-binding
protein.RhebbindingtoGTPisregulatedbytheTSC1/TSC2
heterodimeric complex that functions as a speciﬁc GTPase-
activating protein (GAP).
AktphosphorylatesandinactivatesTSC2,thusincreasing
the amount of active GTP-Rheb that binds and activates
the raptor-mTOR complex. Two main signaling pathways
originate downstream the raptor-mTOR complex: the p70S6
kinase (p70S6K) and the eIF4E-binding protein1 (4E-BP1)
pathway. The p70S6K is a serine/threonine protein kinase,
which regulates the synthesis of factors involved in the
proteinsynthesismachinery,includingtheribosomalS6pro-
tein, and the translational regulators eukaryotic translation
elongation factor 2 (eEF2) kinase and eukaryotic translation
initiation factor 4B (eIF-4B).
The 4E-BP1 pathway regulates the activity of eukaryotic
translation initiation factor 4G (eIF-4G) protein, which is
involved in cap-dependent mRNA translation. After phos-
phorylation by raptor-mTOR, 4E-BP1 releases the eukary-
otic translation initiation factor 4E (eIF-4E) allowing it to
interact with eIF-4G, thus activating cap-dependent mRNA
translation [45].
Akt also directly regulates gene transcription by promot-
ing inactivation of transcription factors of the forkhead box
“Other” (FoxO) family. In the basal state FoxO proteins are
located in the nucleus where they activate the transcription
of molecules relevant to metabolism, apoptosis promotion
and cell cycle inhibition [46–49]. Following phosphorylation
by Akt, FoxO factors are bound by 14-3-3 proteins and
sequestered in the cytoplasm [50–52].
The PI3K/Akt pathway is negatively regulated by the
lipid phosphatase PTEN, which dephosphorylates PIP3 [53].
PTEN activity is often reduced in cancer by mutations,
underlying the key role of Akt pathway in cancer biology
[54].
The second major signaling pathway downstream the
IR and the IGF-IR involves Ras, a GTP-binding protein
that cycles from the active (GTP-bound) to the inactive
(GDP-bound) form [42]. Ras is activated by Ras guanine
nucleotide exchange factor mSOS, which binds the SH3
domain of the adaptor Grb2. Grb2 couples the Ras/mSOS
complex to the IR or IGF-IR by binding both to phos-
phorylated Shc and IRS proteins. Both IRS proteins and
Shc compete for the same phosphosites on the receptor
transmembrane domain [55]. After activation, Ras recruits
to the membrane and activates the serine/threonine kinase
Raf, which phosphorylates the dual speciﬁcity kinase MEK
that in turn phosphorylates and activates ERK1/2 kinases.
Inactive ERK1/2 is mainly located in the cytoplasm where
it forms a MEK/ERK heterodimer [56]. After activation,
ERK1/2 translocates to the nucleus where it phosphorylates
a number of substrates involved in the transcription acti-
vation of several genes [42, 57, 58]. Moreover, activated
ERK1/2 phosphorylates also numerous substrates in the
cytoplasmic compartment implicated in cell growth and
survival [58], such as p90 ribosomal S6 kinases (RSKs).
RSKs inactivate proapoptotic proteins and contribute to
positively regulate mRNA translation through p70S6K and
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2.3. The IGF System in Cancer Development. Both epide-
miological and experimental evidences have suggested a
crucial role of the IGF system in cancer development and
progression. Elevated plasma concentrations of IGF-I have
been linked to an increased risk for several malignancies
[59–62]. In particular, subjects with serum IGF-I levels in
the upper quartile of the normal range have been shown
to be at increased risk of premenopausal breast cancer and
other cancers, such as prostate, lung, colorectal, endometrial
and bladder as compared to subjects who have values in the
lower quartile [34, 59, 60, 62, 63]. Evidences supporting a
correlation between IGF-I levels and cancer risk arise also
from acromegalic patients. Indeed, epidemiological studies
suggestthathighGHandIGF-Ilevelsinacromegalyareasso-
ciated with an increased incidence of various malignancies,
including colon cancer [64].
More recently, it has also become evident that high
circulating levels of insulin are an important factor of cancer
promotion. Insulin resistance and associated compensatory
hyperinsulinemia are common features of obesity and type
2 diabetes. In western countries obesity now occurs in
approximately 30% of the general population and type 2
diabetes in 5-6%. The prevalence of both these disorders
increases with age. Both obesity and type 2 diabetes are
associated with an increased risk for many forms of cancer,
including cancer of the breast, colon, liver, pancreas, kidney
and others [7, 8, 65]. Actually, hyperinsulinemia seems to be
the major link between these disorders and cancer [4] and is
also associated with a poor cancer prognosis [66].
Moreover, a variety of in vitro and in vivo studies
have provided evidences of a complex dysregulation of
t h eI G Fs y s t e mi nc a n c e rc e l l sa n dh a v ee l u c i d a t e daf e w
mechanismsbywhichthisdysregulationmayresultincancer
promotion. The IR and the IGF-IR do not appear mutated
in cancer but are often overexpressed [67–69]. With regard
to IR, it is worth mentioning that only one of the two
IR isoforms, the A isoform or IR-A, is overexpressed in
cancer [70]. Interestingly, IR-A is a high aﬃnity receptor
not only for insulin but also for IGF-II [71]. As a further
layerofcomplexity,cancercellsexpresshighlevelsofIR/IGF-
IR hybrid receptors as a consequence of IGF-IR and IR
overexpression [72].
Moreover, cancer cells often show abnormal autocrine/
paracrine production of both IGF-I and IGF-II, potent
mitogens that bind both the IGF-IR and the IR-A [73, 74].
Several studies have demonstrated that forced expression of
IGF-I and IGF-II in transgenic animal is associated with
accelerated cancer development [75–78].
IGF system dysregulation/overactivation resulting from
receptor and ligand abnormal expression may favor cancer
progression by various mechanisms that depend on the
constitutive activation of the two main branches of intracel-
lular signaling, the PI3K/mTOR and the ERK1/2 signaling
pathways. Interestingly, PTEN, a lipid phosphatase impor-
tant for restraining the PI3K pathway, is often inhibited in
human carcinomas and may contribute to the abnormal
signaling of the IGF system [79]. This abnormal signaling
leads to various eﬀects, including upregulation of cyclin D1
andcyclin-dependentkinase4(CDK4),retinoblastoma(RB)
phosphorylation and activation of cyclin E [80, 81]a n d
enhanced expression of matrix metalloproteases (MMPs)
[82].
This eventually results in the promotion of cell prolifer-
ation and survival and enhanced cell migration [83]. Finally,
the IGF-IR has also a crucial permissive role for anchorage-
independent cell growth, which is strictly associated with
the malignant phenotype [84, 85]. In accordance with these
ﬁndings, IGF-IR knocking-out prevents cell transformation
by several oncogenes [86, 87]. IR has similar although not
identical eﬀects as the IGF-IR. IR overexpression is also
associated with a ligand-dependent transformed phenotype
[88, 89] and is able to stimulate growth [90, 91]a n d
chemotaxis [92, 93]. Finally, IGF system dysregulation in
cancer induces resistance to radiation and various other
targetedandnontargetedcancertherapiesandhasstimulated
thedevelopmentoftherapeuticalagentsabletotargetIGF-IR
signaling in cancer [94, 95].
3. Anticancer Effects of PPAR-γ Agonists
3.1. PPARs Family, Expression and Ligands. PPARs (peroxi-
some proliferator activated receptors) belong to the nuclear
receptor family, and recently have emerged as transcription
factors that regulate diverse aspects of metabolism [96].
To day, three PPARs have been identiﬁed—PPAR-α,
PPAR-β (known also as δ) and PPAR-γ (Figure 2(a)). PPAR-
α is expressed in liver, hearth, muscle and vascular wall
whereas PPAR-β/δ is mainly expressed in skin, brain and
adipose tissue [9, 97]. PPARs regulate gene expression
upon ligand binding that drives heterodimerization with the
retinoidXreceptor(RXR)andsubsequentbindingtospeciﬁc
response elements located in the promoter regions of target
genes (Figure 2(a)).
Due to his abundance in adipose tissue, pancreatic β-
cells,vascularendotheliumandalsoinmacrophages,PPAR-γ
is widely studied. Moreover, PPAR-γ is the molecular target
for the synthetic thiazolidinediones (TZDs), clinically used
as insulin sensitizers in patients with type II diabetes. Seven
PPAR-γ mRNAs have been identiﬁed. PPAR-γ-1 and -2 are
expressed mostly in adipose tissue and large intestine; lower
levels are found in kidney, liver and small intestine. PPAR-
γ-3 is found in adipose tissue and large intestine, PPAR-γ-4
and-5areexpressedonlyinmacrophages,whereasPPAR-γ-6
and -7 are found in adipose tissue [98].
T h em o l e c u l eo fP P A R - γ consists of an N-terminal
domain (also called A/B domain), which is responsi-
ble for ligand-independent transcriptional regulation. The
DNA-binding domain (or C) contains two zinc-ﬁnger-like
and an α-helical DNA binding motifs. Through the C
domain, PPAR-γrecognizes PPRE (Peroxisome Proliferators
Response Element) sequences in the regulated promoter
regions. In the C-terminal is present the ligand-binding
domain that potentiates the PPAR-γ ability to dimerize
with RXR and recruit coactivators, such as Steroid Receptor
Coactivator 1 (SRC1), Peroxisome Proliferator Receptor-γ
Coactivator 1α (PGC-1α), TRAP220/PPARγ binding protein
(PBP), and p300/CREB Binding Protein (CBP) (Figure 2(b))
[99–101]. The activation of PPAR-γ by its ligands leadsPPAR Research 5
concomitantly to its ubiquitination and eventually to protea-
some degradation.
The ligand-binding pocket of PPARs is largerthan that of
other nuclear receptors and allows the binding for a variety
of ligands. In addition to TZDs (exogenous agonists), these
ligands include peroxisome proliferators such as nanenopin,
cloﬁbric acid and warfarin [102, 103]. Although endogenous
ligands are yet not well deﬁned, it has been shown that
mono-andpoly-unsaturatedfattyacidsandarachidonicacid
metabolites may activate PPARs [104, 105].
3.2. PPAR-γ and Cancer: Mechanisms Involving Diﬀerentia-
tion, Proliferation and Apoptosis. TZDs have been used for
the treatment of hyperglicaemia in type II diabetes since
1997. Troglitazone was the ﬁrst of this class of drugs intro-
duced into clinical practice, but it was withdrawn because
of liver toxicity. Currently, pioglitazone and rosiglitazone are
the only compounds licensed for the treatment of patients
with type II diabetes.
Recently, the interest in TZDs as potential anticancer
agents has been raised by observations that TZDs and other
PPAR-γ agonists possess PPAR-γ dependent and indepen-
dent antitumor eﬀects [106]. Thus, TZDs in combination
with chemotherapy drugs or other targeted therapies may
represent a promising tool in the treatment of malignancies
[106].
The molecular basis for the antitumor action of PPAR-γ
agonists remains incompletely elucidated. Numerous studies
support the notion that PPAR-γ activation induces apoptosis
and thus exerts anticancer eﬀects [107]. For instance, in
lung cancer cells troglitazone triggered apoptotic response
in PPAR-γ and ERK1/2 dependent manner [108]. Trogli-
tazone treatment reduced the antiapoptotic protein, Bcl-
2, and caused nuclear accumulation and colocalization of




In addition to apoptosis, PPAR-γ activation may reduce
tumor development by halting cancer cell proliferation
[110]. One well-know mechanism for suppressing prolifera-
tion involves cell cycle arrest. Cyclins are cell cycle regulators
that speciﬁcally activate cyclin-dependent kinases (CDKs).
Due to their role in cell cycle control, cyclins are potential
oncogenes: in fact, cyclin D1 is overexpressed or ampliﬁed in
several human cancers [111, 112].
Exposure to TZDs for 24 hours may cause G0/G1 cell
cycle arrest [113, 114]. TZD treatment not only decreased
protein levels of cyclin D1, but also reduced proliferating
cell nuclear factors such as pRb and Cdk4, and increased
the cyclin-dependent kinase inhibitors p21 and p27, in a
time dependent manner [114]. Again, in thyroid anaplas-
tic cancer rosiglitazone induced growth arrest increasing
cyclin-dependent kinase inhibitors p21 and p27, reducing
cyclin D1 expression as well as activating Rb protein
[109].
Another mechanism by which PPAR-γ activation may
act as tumor suppressor is through the promotion of
cellular diﬀerentiation. In cultured breast cancer, PPAR-γ
ligands caused extensive lipid accumulation and changes
in epithelial gene expression associated with a more dif-
ferentiated, less malignant state [115]. In lung cancer
cells, ciglitazone induced diﬀerentiation [116] and in thy-
roid cancer cells, rosiglitazione induced the expression of
thyroid-speciﬁc diﬀerentiation markers suggesting a par-
tial reversion of the epithelial mesenchymal transition
[109].
The mechanism of TZD-induced diﬀerentiation has also
been well studied in adipocytes and involves the interaction
with the Wnt pathway. It has been shown that PPAR-γ and
GSK3β interact through CAAT/enhancer binding proteins
(C/EBP). GSK3β-induced C/EBPβ activates PPAR-γ, that in
turn activates the diﬀerentiating factor C/EBPα leading to
the production of adiponectin and completion of adipocyte
diﬀerentiation [117, 118].
Moreover, PPAR-γ and β-catenin expression seems to
be correlated [119]. Direct interactions among PPAR-γ,
RXR and β-catenin have been found recently in human
kidney embryonic HEK293 cells and in human metastatic
prostate cancer LNCaP cells [120, 121]. PPAR-γ can function
to suppress Wnt signaling by targeting phosphorylated β-
catenin to proteasome. In agreement with these ﬁndings, in
3T3-L1 adipocytes, β-catenin mRNA and protein levels were
decreasedbyPPAR-γ activation[122].Theabovedataimply
a positive feedback mechanism involving GSK3β,P P A R -
γ and β-catenin that ampliﬁes signals for diﬀerentiation
and inhibits signals for proliferation in both adipocytes and
cancer cells.
Another mechanism by which PPAR-γ agonists may
mediate suppression of tumor initiation and progression
is the inhibition of angiogenesis and the downregulation
of tumor microenvironment inﬂammation [123, 124]. The
PPAR-γ antiinﬂammatory actions are of relevance to the
treatment of atherosclerosis as well as cardiovascular disease
[125]. However, given the association of chronic inﬂamma-
tion with cancer risk, they may also prove important for the
treatment and prevention of cancer.
In summary, PPAR-γ agonists may act as negative
regulators of cancer growth and progression, by multiple
mechanisms. Some of these eﬀects may be related to
the direct and/or indirect interaction of PPAR-γ agonists
with the IGF system. We will herein review the molecular
mechanisms by which PPAR-γ agonists cross-talk with the
IGF-system signaling and may aﬀect cancer biology.
4. Cross-Talk betweenPPAR-γ Agonists and
IGFSystemSignaling
Conﬂicting evidence has led to confusion about whether
PPAR-γ exerts an inhibitory or stimulatory eﬀect on tumori-
genesis (Table 1). It is generally considered as a tumor-
suppressor, yet has been suggested to exacerbate the growth
of certain tumors. The janus-face (anti- versus protumor
function) of PPAR-γ and its ligands, can be explained
by considering the interaction with IGF system and its
downstream signaling pathways as MAPK, PI3K and mTOR































• Interaction with MEK1, β-catenin
• EGF-R transactivation
• Calcium inﬂux
• Induction of signaling pathways






Figure 2: Components and signaling pathways of the PPAR system. (a) Schematic representation of components of the PPAR system. PPARs
act as ligand-activated transcription factors that are responsive to the lipid status of the cell. The physiological ligands for these nuclear
receptors are typically unsaturated fatty acids (FFAs) and their eicosanoid products. PPARs regulate the expression of genes that encode
proteins involved with lipid metabolism (oxidation), leukotriene degradation, energy balance, eicosanoid signaling, cell diﬀerentiation and
tumorigenesis. PPARs are diﬀerentially expressed in the various tissues. PPAR-α is highly expressed in liver, kidney, heart, brown adipose
tissue, and the intestine, whereas PPAR-γ is found in adipose tissue, small intestine, and lymphatic tissues. PPAR-β is ubiquitous. (b) PPAR-
γgenomic versus nongenomic actions.P P A R - γ belongs to the class of nuclear receptors, with a typical modular structure composed by at
least an N-terminal transactivation domain and a DNA binding domain (DBD). Upon ligand binding, a conformational change leads to the
release of corepressors (NCoRs), recruitment of coactivators (NCoAs), heterodimerization and transactivation of PPRE-related promoters.
This genomic function of PPAR-γ controls immune response, as well as lipid and glucose metabolism. Nuclear PPAR-γ exerts also a negative
cross-talk towards major proinﬂammatory and promitotic transcription factors. Cytoplasmic PPAR-γ, by interacting with proteins (MEK1,
β-catenin) and activating transmembrane proteinases, elicits rapid and transient nongenomic eﬀects that modulate EGF-R transactivation,




(1) Inhibition of PPAR-γ genomic
functions by MAPK [108, 126–143]
(2) PPAR-γ nongenomic functions
(MAPK activation, MMP2, and VEGF
production)
Antitumorigenic eﬀects References
(1) PPAR-γ genomic eﬀects
[109, 144–151] (2) Induction of PTEN expression
(3) Inhibition of p70S6K
4.1. PPAR-γ and MAPK Cross-Talk: A Complex Issue Aﬀecting
IGFSignaling. Aswehavealreadymentionedintheprevious
section (the IGF system signaling pathways) the MAPK
cascade transmits proliferative signals generated by cell
surface receptors and cytoplasmic elements to the nucleus
[152, 153].
The RTK-Ras/Raf/Mek/Erk pathway is overactivated in
∼30% of human cancers [154] where it provides growth and
survival signals. Growth factors can be overexpressed and
receptortyrosinekinasesmutatedorampliﬁed,therebystim-
ulatingconstitutive receptor tyrosine kinases signaling [155].
One of the upstream regulators of MAPK pathway is the IGF
signaling axis. The binding of IGF-I or IGF-II to the IGF-IR
initiates conformational changes that triggers autophos-
phorylation and subsequent activation of Ras/Raf/Mek/Erk
cascade.Thus,theIGFsystemderegulationthrougheither(i)
IGF-IR overexpression or (ii) autocrine/paracrine produc-
tion of IGF-I and IGF-II or (iii) autocrine IGF-II/IR-A loop
activation, can induce constitutive stimulation of the MAPK
cascade.
The IGF mediated MAPK activation, in turn, may
modulatethegenomicactivityofPPAR-γ bytheinhibitionof
its antiproliferative and prodiﬀerentiating functions, thereby
contributing to the tumor promoting role of IGF pathway.
The points of interactions between MAPK pathway and
PPARγ are various [156, 157] and include the following.
(1) Phosphorylation of a serine residue of PPAR-γ (and
itscofactors)byERK1/2, JNKandp38 MAPKs(Figure 3(D))
[158]. Phosphorylation of PPAR-γ by MAPKs is directed
against Ser82/112 (mouse) or Ser84/114 (human) within a
consensus MAPK-motif (PxSPP) [159, 160]. This MAPK-
dependent mechanism, modulates the ability of PPAR-γ
to form a heterodimer with RxR and bind PPRE, thus
inducing gene transcription (genomic activity of PPAR-
γ)[ 161]. The PPAR-γ conformational change, induced by
phosphorylation, inhibits its ligand-binding aﬃnity [162],
decreases its binding to PRRE [163] and the recruit-
ment of coactivator/corepressor complexes [164]. Moreover,
PPAR-γ phosphorylation promotes its inactivation by poly-
ubiquination, proteasomal degradation and sumoylation
[165]. The suppression of PPAR-γ genomic activity, by








































Figure 3: Cross-talk between PPAR-γand IGF system downstream signaling pathways. The points of interaction between PPAR-γ and
MAPK/PI3K pathways occur at diﬀerent levels and are indicated as arrows (activation) or bars (inhibition). In some cell contexts PPAR-
γ ligands reduce MEK1/2 protein expression (A) and inhibit ERK1/2 phosphorylation (B). However, in other cell systems, PPAR-γ
agonists may activate ERK1/2 (C). Alternative mechanisms of interaction between PPAR-γ and MAPK/PI3K pathways include (D) ERK-
mediatedPPAR-γ phosphorylationatSer84/114;(E)MEK1/2-dependentPPAR-γ nuclearexportfollowedbyPPAR-γ degradation;(F)PTEN
upregulation; (G) mTOR downregulation via activation of AMPK; (H) inhibition of p70S6K phosphorylation.
the antiproliferative, antiinﬂammatory and prodiﬀerentiat-
ing role of PPAR-γ and is supported by several in vitro
studies, conducted in normal as well as in cancer cells. For
example, it has been shown that TFNα suppresses PPAR-γ
function in hepatic stellate cells [126] as do the PGF2α in
adipocytes [127], proinﬂammation lipid mediators HODEs
in colon and prostate cancer cells [128], EGF and PDGF
in preadipocytes (3T3-L1) and in murine ﬁbroblasts (NIH-
3T3) [129, 130]. In addition, other studies have revealed
the poly-ubiquination and proteasomal degradation upon
S82/112 phopshorylation of PPAR-γ as a mechanism of
PPAR-γ inactivation in adipocytes [131, 132], breast [133]
and colon cancer cells [134], after IFNγ, Her-2 and gastrin
stimulation, respectively.
In summary, altogether, these in vitro evidences indicate
that MAPK stimuli, through phosphorylation, inactivate
PPAR-γ-dependent gene transcription in cancer cells and
are in line with the antitumor promoting role of PPAR-γ
[135, 136].
(2) Modulation of PPAR-γ’s nucleo-cytoplasmic com-
partmentalization induced by MEK1, upon cell stimulation
with mitogens and PPAR-γ-ligands (Figure 3(E)).
Burgermeister et al. [131] have demonstrated that MEK1
and PPAR-γ directly interact in resting cells and this
association induces a nuclear export of PPAR-γ, leading
to reduction in its genomic functions. Cytosolic PPAR-
γ, then, is either subjected to proteosomal degradation or
shunted to other cell compartments (ER/Golgi, cytoskeleton,
lipid droplets, caveolae) to trigger extranuclear/nongenomic
actions. Although the functions of exported PPAR-γ remain
to be completely elucidated, it seems that this dynamic
change in subcellular localization of PPAR-γ may inﬂuence
the balance between its tumor suppressive and tumor
promoting activities. Several studies have reported that
PPAR-γ is mainly present in the nucleus of non neo-
plastic tissues, where it exerts classical genomic functions
(antiinﬂammatory, antiproliferative, prodiﬀerentiating). In
contrast, it is expressed predominantly in the cytoplasm of
tumor tissues of inﬁltrating breast carcinoma and salivary
duct carcinoma, where it is associated with increased tumor
aggressiveness and poor clinical prognosis of patients [137,
138]. A diﬀerential subcellular distribution of PPAR-γ has
also been shown in human stomach cancer tissues, where
the nucleo:cytoplasm ratio of PPAR-γ increased along with
the progression of intestinal metaplasia to undiﬀerentiated
cancer [166]. Notably, in lung tumor samples, PPAR-
γ expression was present in both the nucleus and the
cytoplasm [167]. These results are indicative of a cor-
relation between cell malignancy and PPAR-γ subcellular
distribution.
In summary, both mechanisms of MAPK/PPAR-γ inter-
action described above (i.e., the MAPK-mediated PPAR-
γ p h o s p h o r y l a t i o na sw e l la st h eM E K - 1d r i v e nn u c l e o -
cytoplasmic shuttle of PPAR-γ), may represent a way for
enabling PPAR-γ nuclear genomic activity and support
the protumor and antiapoptotic role of IGFI system and8 PPAR Research
its downstream signal-transduction components Ras/Raf/
MEK/ERK.
(3) Inhibition of MAPK pathway mediated by PPAR-γ
ligands.
In some cell contexts and tissue-speciﬁc systems, it
has been shown that PPAR-γ agonists speciﬁcally abol-
ished the phosphorylation of ERK1/2 in a dose and time
dependent manner (Figure 3(B)) and also downregulated
the protein expression of MEK1/2 (Figure 3(A)), inducing
cell growth arrest and apoptosis [137, 168]. The inhibi-
tion of MAPK signals mediated by PPAR-γ ligands, is in
line with their antiproliferating and proapoptotic functions
and is in concordance with data from literature show-
ing that PPAR-γ agonists block the biological actions of
IGF-I.
The implication of these ﬁndings is that PPAR-γ agonists
may represent a reasonable therapeutic approach in tumors
where MAPK and/o IGF-I pathways are overactivated.
However, several in vitro and in vivo studies have pro-
vided evidences indicating that PPAR-γ ligands may also
trigger promitotic and prosurvival signals in certain cell
contexts. It is well known that PPAR-γ agonists exhibit
rapid (within 15 minutes) non genomic eﬀects, including
activation of signaling pathways as MAPK and PI3K/mTOR
[139], upregulation of p21 and p27 [140, 169], induction of
p53 [170], transient alterations in mitochondrial functions
[171]. An early response of ERK1/2 in presence of PPAR-
γ ligands has been reported in many studies and occurs
under largely unknown mechanisms, which may or may
not involve PPAR-γ. Takeda et al. [172] demonstrated that
15d-PGJ2 and thiazolidinediones activate the MEK/ERK
pathway through PI3K pathway, leading to c-Fos mRNA
expression and DNA synthesis [108, 141]. Ciglitazone and
15d-PGJ2induceactivationofMAPKsinprimaryastrocytes,
preadipocytes,chondrocytesandliverepithelialcellsthrough
aP P A R - γ independent mechanism [142, 168]. Patel et al.
[140] have reported that troglitazone activates both PI3K
and MAPK signaling networks. Furthermore, in colon
carcinoma cells, it has been found that tiazolidinediones,
through ROS production and ERK activation, induce matrix
metalloproteinase 2 (MMP2) and subsequently increase
tumor cell invasion [142]. Yet, in human breast cancer cells
MCF7, 15d-PGJ2 upregulates VEGF and induces PPAR-
γ-independent ERK activation, thereby stimulating angio-
genesis and proliferation [143]. This positive cooperation
between PPAR-γ and components of MAPK cascade in
promoting tumor initiation and progression may explain
the absence of therapeutic beneﬁts of TZDs in some cancer
patients and adds signiﬁcant complexity to the PPAR-γ
functions in cancer biology. Furthermore, the nongenomic
rapid activation of ERK signaling cascade, in presence of
PPAR-γ ligands, can aﬀect the PPAR-γ genomic action, via
ERK1/2—mediated PPAR-γ phosphorylation or via MEK—
dependent PPAR-γ nuclear export. This overlap between
genomic and nongenomic eﬀects of PPAR-γ ligands, may
explain both pro- and antitumor actions of PPAR-γ agonists.
However, nowadays, the mechanisms underlying cell deci-
sion for pro- versus antiproliferative responses upon PPAR-γ
ligands stimulation, are unknown.
So far, PPAR-γ emerges as a context-speciﬁc tumor
modulator, whose functions are modulated by PPAR-γ-
independent eﬀects of its ligands and by a synergic or antag-
onistic cooperation with IGF-I/MAPK cascades. It is possible
tospeculatethatintumorswherePPAR-γ expression/activity
is low and the MAPK signaling network is constitutively acti-
vated by various stimuli, including IGF dependent signals,
PPAR-γ ligands exert antitumor and antiproliferating eﬀects.
In this condition, the combined use of kinase inhibitors and
PPAR-γ agonists may be beneﬁcial as anticancer therapeutic
strategy. Alternatively, the interactions between PPAR-γ and
other important survival pathways, such as PI3K/mTOR,
may inﬂuence cell fate and determine whether pro- or
antitumorigenic responses are induced. In light of these
considerations, elucidating the non genomic pathways of
PPAR-γ ligands and delineating the transduction signals
underlying the cross-talk between PPAR-γ and other key
survival signals is likely to yield new therapeutic targets for
development of anticancer therapies.
4.2. Cross-Talk between PPAR-γ and PI3K. Besides the
MAPK cascade, alternative antiapoptotic and prosurvival
signal transduction pathways, such as PI3K and mTOR, have
been identiﬁed for the IGF-IR signaling axis (for a detailed
description see Section 2.2).
The points of interaction between PPARs family and
PI3K pathway involve diﬀerent components of IGF-I/PI3K
signaling cascade.
For example, as shown in adrenocortical cancer cells
(SW13 and H295R), PPAR-γ ligands can rapidly interfere
with the Akt phosphorylation/activation, which mediates
IGF-I stimulated proliferation [173]. These evidences sup-
port the antiIGF-I role of PPAR-γ agonists observed in
a wide variety of tumor cancer cell lines and tissues.
A possible mechanism for this antagonistic eﬀect is the
increase in PTEN expression (Figure 3(F)). In line with this
hypothesis, we have found that in human anaplastic cancer
cell lines, rosiglitazone, via PTEN upregulation, inhibited
IGF-I mediated biological eﬀects such as cell migration,
survival and anchorage-independent growth [109]. Similar
results have been reported in human hepatocarcinoma cell
lines (BEL-7404 and Hep3B) [144, 145]a sw e l la si nc o l o n
cancer cells (Caco2) [146], in breast cancer cells (MCF-7)
[146], in nonsmall cell lung carcinoma cells (H1792, H1838
and A549) [147, 148], and in pancreatic cancer cells (AsPC-
1) [149]. However, the exact molecular mechanism behind
PTEN induction, due to PPAR-γ agonists, has yet to be
fully understood. Two hypotheses have been proposed to
explain the interaction between PTEN and PPAR-γ:P P A R -
γ directly regulates PTEN transcription and/or PPAR-γ
regulates secondary unknown factors that, in turn, regulate
PTEN [146, 174]. Furthermore, because PTEN expression
can be regulated by interfering with its transcription activity
or by inducing posttranscriptional modiﬁcations, it is also
possiblethatPPAR-γ agonistsinducePTENoverexpression
by decreasing its degradation [175, 176]. Aside from the
speciﬁc mechanisms involved, the regulation of PTEN levels
by PPARγ agonists, provides a powerful mechanism to shut
down the basal or stimulated signals of PI3K cascade andPPAR Research 9
could be exploited for future treatment of cancers in which
PTEN is downregulated/lost and IGF-I-mediated signals are
ampliﬁed.
The link between PPAR-γ and PI3K pathway involves
also another component of PI3K signaling axis: the
mTOR/p70S6K cascade. As we have previously discussed,
mTOR pathway is coregulated by IGF-I-Akt signaling to
ensure both a reasonable level of nutrients and a positive
mitogensignalforcellgrowthanddivision.TheIGF-Isystem
regulates the mTOR axis through the phosphorylation
and inhibition of the TSC1/2 complex by Akt, which in
turn activates Rheb and mTOR. Stimulation of the IGF-
IR activates the PI3K/Akt/mTOR cascade and triggers an
mTOR-dependent decrease in IRS-1 expression and phos-
phorylation, leading to PI3K/Akt/mTOR inactivation [177,
178]. This feedback inhibition could paradoxically reduce
the antitumor eﬀect of mTOR inhibition by enhancing IGF-I
signaling.
Thiazolidinediones have been recently shown to modu-
late and regulate the IGF-I/Akt/mTOR/p70S6K pathway. In
endothelial cells, troglitazone has been found to decrease
p70S6K phosphorylation (Figure 3(H)) and to inhibit pro-
tein biosynthesis via a protein phosphatase 2A (PP2A)-
dependent mechanism, which do not involve neither mTOR
nor PPARγ [150]. An alternative mechanism through which
PPARγ agonists inhibits phosphorylation of p70S6K is
the activation of AMPK (Figure 3(G)) [151]. AMPK is a
multisubstrate enzyme induced by increase in AMP level
during metabolic stress in response to exercise, hypoxia and
fasting condition and it plays a major role in the regulation
of energy control [179]. The phosphorylation of this fuel-
sensing enzyme, negatively regulates mTOR by directly
phosphorylating the TSC1/2 complex [180]. The mTOR
inhibition induced by AMPK is in line with the existence of
a link between AMPK and the growth inhibition of some
cancer cells [179, 181, 182] .T h ea c t i v a t i o no ft h i se n z y m e
induced by thiazolidinediones has been supported by several
in vitro studies. As He et al. [151]h a v er e p o r t e d ,P P A R γ
agonists induced phosphorylation of AMPK in mouse skin
keratinocytes most likely via a PPARγ-indipendent mech-
anism, which subsequently suppresses IGF-I-induced cell
proliferation by inhibiting mTOR activity and phosphory-
lation of p70S6K. Yet, Han and Roman [147]h a v ef o u n d
thatrosiglitazoneinhibitsgrowthofnonsmallcelllungcarci-
noma cells via upregulation of AMPK, thereby downregulat-
ing the mTOR/p70S6K pathway through PPARγ-dependent
and/or PPARγ-independent mechanisms. Although it is not
well known how thiazolidinediones rapidly activate AMPK,
thesubsequentinhibitionofmTORsignalingpathwaycanbe
considered a mechanism by which thiazolidinediones exert
an antiIGF-I function as well as an insulin-sensitizing action.
As thiazolidinediones target both the IGF system and
other crucial protumor signals downstream of IGF-IR,
their use in monotherapy or in combination with the
small-molecule TK inhibitors or with antibodies directed
against the IGF-IR, may be eﬀective to achieve the maximal
therapeutic beneﬁt and may even be useful to reduce the side
eﬀectsassociatedwithIGF-IRtargetedtherapy(insulinresis-
tance, hyperglycaemia, hyperinsulinaemia, eﬀect on growth
and development of normal cells and tissues with high
level of cellular turnover, neurotoxicity), thereby improving
tolerability and/or eﬃcacy. Furthermore, the use of PPARγ
agonists may represent a valid therapeutic tool to circumvent
the resistance that some tumors develop to therapies target-
ing PI3K/mTOR signaling pathways.
4.3. PPAR-γ Agonists May Regulate IGFs Bioavailability. Hy-
perinsulinemia and insulin resistance, commonly observed
in type 2 diabetes and others metabolic disorders, are
associated with an increased risk of tumor development in
severaltissues.CompensatoryactivationofIGF-Isignalingin
insulin resistance states is believed to be responsible for this
association [37, 183]. Thiazolidinediones are currently used
to treat type 2 diabetes mellitus and, by ameliorating insulin
resistance, have the potential to reduce IGF-I bioavailabil-
ity in these patients. Furthermore, inhibiting the tumor
promoting activity of IGF-I they may provide additional
tumor preventive beneﬁt to type 2 diabetes patients. The
local availability of IGFs ligands is abnormally high in
many cancers where they serve as endocrine, autocrine and
paracrine regulators of survival and proliferating signals
mediated by IGF-IR. The IGFs bioavailability, as well as the
IGFs bioactivity, is modulated by IGF-I binding proteins
(IGFBPs) and IGFP proteases. In general, IGFBPs limit IGFs
access to IGF-IR, reducing the bioactivity of these growth
factors. However, in some cell contexts, IGFBPs can increase
rather than decrease IGF-mediated eﬀects, by presenting
and slowly releasing IGF-I for receptor interactions, while
protecting the receptor from IGF-I induced downregulation
[35].ThisphenomenonhasbeenshownforIGFBP1,IGFBP3
and IGFBP5 [37, 184]. Furthermore, IGFBPs (especially
IGFBP3) may also regulate cell growth and apoptosis in
IGF-I independent manner [185]. Alterations of individual
components of IGF cascade (IGFs/IGF-IR/IGFBPs) may
potentially contribute to cancer initiation and progression
[186]. Several evidences have suggested that the eﬀects of
TZDs on cell proliferation and diﬀerentiation can be due to a
modulationinIGFs/IGFBPslevels.Lecka-Czerniketal.[187]
reported, that, in primary and transformed marrow stromal
cells and in mouse liver cells, rosiglitazone, suppresses IGFI,
IGFIIandIGFBP-4levelsandreducestheexpressionofIGFI-
R and IGFII-R, whereas no eﬀect was observed in IGFBP-
3 expression. These changes in IGF signaling eﬀectors were
evident within 72 hours and occurred at transcriptional as
well as posttranscriptional levels. In addition, the modu-
lation of the IGF system mediated by PPARγ ligands, was
associated with suppression in several cell cycle genes. These
ﬁndings are in line with other reports demonstrating the
antiproliferative eﬀect and the antiIGF-I role of PPARγ ago-
nists [96, 188]. Although the PPARγ mediated suppression
of IGF-I levels could limit cell proliferation and induce
apoptosis in speciﬁc cell context, the authors pointed out
that the drop in circulating IGF-I may negatively impact the
skeleton, by impairing osteoblastic diﬀerentiation and action
[187]. These observations may have clinical signiﬁcance
and should be taken into account when TZDs are used in
young patients that are still acquiring peak bone mineral10 PPAR Research
density. However, further studies are needed to better under-
stand the role of IGF-I in bone cell turnover. Interactions
between PPARγ and IGF-I signaling mediators have also
beenseeninhumanovariancells.Inexperimentscarriedout
in vitro, TZDsincrease IGFBP-1 production by ovarian cells
in the absence of insulin but enhanced insulin-mediated
inhibitionofIGFBP-1production.Thelatterinsulinsensitiz-
ing eﬀect, could increase the bioavailability of IGFs, thereby
enhancing the IGF-I mediated ovarian follicle proliferation
andsteroidogenesis[189].TheseoppositeeﬀectsonIGFBP-1
production (insulin-independent stimulation versus insulin-
dependent inhibition) observed in vitro, contrast with in
vivo data showing that TZDs increase of IGFBP-1 synthesis,
presumably because they reduce hyperinsulinemia [190].
Stimulation of insulin receptor or IGF-IR as well as the
modulation of circulating IGFBP-1 levels by TZDs may
increase ovarian sensitivity to insulin and/or IGFs. The
subsequent eﬀect is the reduction of ovarian androgen
production and the improvement of ovulatory function
[191]. Although the role of TZDs in mediating ovarian
function through IGFBP-1 synthesis modulation needs to
be clariﬁed, the interactions between PPARγ agonists and
IGF system may be important under both physiological
(ovulation and steroidogenesis) and pathological conditions
(polycystic ovary syndrome and syndromes of extreme
insulin resistance). The eﬀect of PPARγ agonists on IGFBP-
1 production has also been studied in HepG2 hepatoma
cells. In these cells, troglitazone is able to increase IGFBP-
1 mRNA expression and secretion in a PPARγ independent
manner [192]. IGFBP-1 mediates critical prosurvival signals
in liver, although it has also been shown to inhibit the
antiapoptotic IGFs functions. Nowadays, the exact role of
I G F B P - 1p r o d u c t i o ni nl i v e rc e l l su p o nP P A R γ agonists
treatment, is yet not understood. The variety of the eﬀects
induced by TZDs on components of IGF-I system is still
under investigation and may be due to the multiple and
alternative signaling pathways they stimulate or inhibit. This
adds signiﬁcant complexity in the understanding of PPARγ
agonists functions in both physiological and pathological
conditions.
4.4. PPAR-γ Agonists: In Vivo Studies. T h er o l eo fP P A R - γ as
a key regulator of metabolism is mainly mediated through
its transcription factor activity in adipose tissue, muscle and
liver. Studies in knock-out mice have elucidated this role and
have demonstrated that insulin sensitization, through PPAR-
γ action, involves adipose tissue maintenance [193–195].
T h ea c t i v a t e dr e c e p t o rw o r k si nan u m b e ro fw a y st o
achieve these eﬀects, including alteration of the expression
of genes involved in lipid metabolism, free fatty acid (FFA)
uptake and storage in adipose tissue [196, 197]. Moreover,
PPAR-γ activation by TZDs has been shown to reduce the
amount of circulating FFA via adipocyte diﬀerentiation and
apoptosis [198]: the number of small adipocytes, able to
accumulate FFA, increases at the expense of hypertrophied
ones that release FFA. As consequence, adipose tissue
mass is increased, so other insulin-sensitive tissues are in
an advantaged position. Glucose metabolism by liver and
muscle is improved and β-cell apoptosis decreased, thereby
increasing insulin secretion in type II diabetic patients.
Another important eﬀect of PPAR-γ activation is connected
with increased adiponectin production from adipose tissue
[196, 199]. Adiponectin signiﬁcantly increases fatty acid
oxidation in human skeletal muscle via activation of AMP-
activated protein kinase, again with increased glucose uptake
[199].
4.5. Eﬀects on Insulin Serum Level and Circulating IGF-I.
TZDs are useful agents in the treatment of hyperglycaemia,
acting as insulin sensitizers and enhancing glucose uptake
via their interactions with PPAR-γ receptors. As already
mentioned, in vivo experiments in diabetic mice conﬁrm
that treatment with PPAR-γ agonists resulted in signiﬁcantly
improved glycaemia and increase in circulating adiponectin
levels [200, 201].
Clinical trials have shown that TZDs lower fasting and
postprandial glucose and it has been demonstrated that
pioglitazone and rosiglitazone at maximal doses can lower
glycosilated haemoglobin by 1–1.5%, on average [9]. More-
over, it has been shown that treatment with rosiglitazone
slowed progression to monotherapy failure more eﬀectively
than metformin or glyburide. Rosiglitazone was also shown
to slow the rate of loss of β-cell function and improve insulin
sensitivity to a greater extent than the other two drugs [202].
Despite the growing amount of clinical data supporting
theroleofPPAR-γ agonistsasinsulin-sensitizers,onlyasmall
number of in vivo studies is available regarding the eﬀect of
PPAR-γ ligands on IGF-I serum level.
Nonetheless, current studies provide some essential and
encouraging information. Lecka-Czernik et al. [187]h a v e
recently focused their attention on PPAR-γ role in the
acquisition and maintenance of bone mass. In yellow obese
agouti mice, rosiglitazone treatment for 8 week lowered
serum IGF-I and reduced IGF-I transcript in liver and
peripheral fat. Similarly, Ackert-Bicknell et al. [203]h a v e
recently analyzed strain speciﬁc eﬀects of rosiglitazone on
bone mass, body composition and serum IGF-I levels. They
found that in the C3H strain, rosiglitazone aﬀects adiposity
and decreased circulating IGF-I levels.
5. Concluding Remarks
It is now widely accepted that IGF system dysregulation
plays an important role in the development of common
human malignancies. Cancer cells often overexpress IGF-IR
andIR-A.Moreover,signalingdownstreamofthesereceptors
is frequently constitutively activated by autocrine/paracrine
production of IGF-I and/or IGF-II.
In addition, hyperinsulinemia, an important feature
associated with the insulin resistance of obesity and type 2
diabetes may stimulate IGF-IR and IR-A in cancer cells and
play a key role in cancer promotion [204–207]. Circulating
levels of IGF-I in the upper quartile of the normal range
may also promote cancer, especially at critical ages such as
childhood and adolescence [36].
The pleiotropic eﬀects of PPAR-γ agonists have several
potential beneﬁcial eﬀects in cancer therapy. Not only PPAR-
γ agonists downregulate both the PI3K and the Ras pathway,PPAR Research 11
which are the two main signaling pathways downstream
receptors of the IGF system, but also they ameliorate insulin
resistanceandlowercirculatinglevelsofinsulinandfreeIGF-
I. One may hypothesize that the janus-face (anti- versus pro-
tumor function) of PPAR-γ and its ligands can be explained
bytheinteractionwithIGFsystemandthatanticancereﬀects
are mainly to be expected in those tumors “addicted” to
the enhanced IGFs signaling. Only scanty data are currently
available regarding the antitumor eﬀect of PPAR-γ agonists
in the clinical setting [17, 106, 108, 208] and more work is
needed in this ﬁeld. Some disappointing results in clinical
studies may be explained by the inclusion of cancers in far
advanced stages. Moreover, in future trials we probably need
to include tumors characterized by IGF system overactiva-
tion and/or tumors occurring in hyperinsulinemic patients.
Finally, in vitro and in vivo studies have demonstrated that
combination therapies, with PPAR-γ agonists together with
other anticancer drugs, including drugs targeting the IGF
system, may provide beneﬁt for the treatment of certain
human cancers. The most promising drugs able to potentiate
the antiproliferative eﬀect of PPAR-γ agonists are platinum-
based chemotherapics, COX-2 inhibitors, paclitaxel, EGFR
tyrosine kinase inhibitors, mTOR antagonists and IGF-IR
inhibitors [148, 209–212]. Although combination therapies
using these agents have been suggested to be eﬀective
in terms of antitumor activity and prevention of drug
resistance, large randomized clinical trials are required for
further evaluation and optimization.
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